{"id":"W1998354077","doi":"10.1378/chest.11-2292","title":"Oral Anticoagulant Therapy","year":2012,"lang":"en","type":"review","venue":"CHEST Journal","topic":"Atrial Fibrillation Management and Outcomes","field":"Medicine","cited_by":1503,"is_retracted":false,"has_abstract":false,"ca_institutions":"St. Joseph’s Healthcare Hamilton; McMaster University; St. Joseph's Hospital","funders":"National Heart, Lung, and Blood Institute; Sanofi; Bristol-Myers Squibb","keywords":"Dabigatran; Rivaroxaban; Medicine; Anticoagulant; Direct thrombin inhibitor; Antithrombotic; Intensive care medicine; Discovery and development of direct thrombin inhibitors; Pharmacodynamics; Adverse effect; Drug; Idarucizumab; Fondaparinux; Pharmacology; Pharmacokinetics; Warfarin; Thrombosis; Surgery; Thrombin; Internal medicine; Atrial fibrillation; Venous thromboembolism","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null}